Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer
This trial is active, not recruiting.
|Condition||advanced hormone sensitive prostate cancer|
|Start date||September 2014|
|End date||September 2017|
|Trial size||111 participants|
|Trial identifier||NCT02229253, 000171|
Patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of one year. In this real-life, non-interventional trial, any cardiovascular events occurring during degarelix therapy will be documented.
Treatment according to standard clinical practice.
Cardiovascular event rate in hormone naïve prostate cancer patients with cardiovascular comorbidity at baseline, treated with degarelix in daily practice
time frame: Up to 1 year
Male participants of any age.
Inclusion Criteria: - Patients with prostate cancer and a history of cardiovascular disease, prescribed degarelix for the treatment of their prostate cancer Exclusion Criteria: - Patients who have received a form of androgen deprivation therapy for their prostate cancer, during the 12 months preceding this study are excluded - Planned intermittent or short-term (< 12 months) degarelix treatment - Planned addition of, or switch to another form of androgen deprivation therapy during the study
Call for more information